This is an attractive therapeutic strategy [22], particularly in lymphomas, where p53 mutations account for less than 15% of all cases [23,24], yet wt-p53 remains dysfunctional due to overexpressed HDM2. This evidence concerns the gene TP53 and lymphoma.